Abstract

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. in certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• C07C 61/00 - Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• C07C 61/00 - Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• C07C 61/12 - Saturated polycyclic compounds

Abstract

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics